Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2022 | The efficacy of tocilizumab in patients with advanced renal AA amyloidosis

Peter Kvacskay • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Tocilizumab

Peter Kvacskay, MD, Heidelberg University Hospital, Heidelberg, Germany, briefly discusses the efficacy of tocilizumab in patients with renal AA amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

More from Peter Kvacskay

Unmet needs in patients with AA amyloidosis with renal involvement
3:46
Unmet needs in patients with AA amyloidosis with renal involvement
Peter Kvacskay • 6 Sep 2022
Strategies to manage renal AA amyloidosis and advances in this space
1:40
Strategies to manage renal AA amyloidosis and advances in this space
Peter Kvacskay • 6 Sep 2022

Related Videos

Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
2:14
Anselamimab in AL amyloidosis: combining and sequencing with plasma cell-directed treatment
Ashutosh Wechalekar • 9 Sep 2026
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
3:04
Phase III CARES subgroup analysis: signal of benefit with anselamimab in kappa AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals